JP7214086B2 - 二環式コア部分を有する新規ｌｘｒモジュレーター - Google Patents

二環式コア部分を有する新規ｌｘｒモジュレーター Download PDF

Info

Publication number
JP7214086B2
JP7214086B2 JP2020572372A JP2020572372A JP7214086B2 JP 7214086 B2 JP7214086 B2 JP 7214086B2 JP 2020572372 A JP2020572372 A JP 2020572372A JP 2020572372 A JP2020572372 A JP 2020572372A JP 7214086 B2 JP7214086 B2 JP 7214086B2
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
halo
independently selected
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020572372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528451A5 (enExample
JP2021528451A (ja
Inventor
ゲーゲ クリスティアン
キンツェル オーラフ
ハンブルッフ エーファ
ビルケル マンフレート
クレモザー クラウス
ドイシュレ ウルリヒ
Original Assignee
オルソバイオ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オルソバイオ，インコーポレイティド filed Critical オルソバイオ，インコーポレイティド
Publication of JP2021528451A publication Critical patent/JP2021528451A/ja
Publication of JP2021528451A5 publication Critical patent/JP2021528451A5/ja
Application granted granted Critical
Publication of JP7214086B2 publication Critical patent/JP7214086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
JP2020572372A 2018-06-28 2019-06-28 二環式コア部分を有する新規ｌｘｒモジュレーター Active JP7214086B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18180450.1 2018-06-28
EP18180450 2018-06-28
PCT/EP2019/067351 WO2020002611A1 (en) 2018-06-28 2019-06-28 Novel lxr modulators with bicyclic core moiety

Publications (3)

Publication Number Publication Date
JP2021528451A JP2021528451A (ja) 2021-10-21
JP2021528451A5 JP2021528451A5 (enExample) 2022-06-16
JP7214086B2 true JP7214086B2 (ja) 2023-01-30

Family

ID=62947921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572372A Active JP7214086B2 (ja) 2018-06-28 2019-06-28 二環式コア部分を有する新規ｌｘｒモジュレーター

Country Status (27)

Country Link
US (3) US11618747B2 (enExample)
EP (1) EP3814331B9 (enExample)
JP (1) JP7214086B2 (enExample)
KR (1) KR102678581B1 (enExample)
CN (1) CN112689630A (enExample)
AR (1) AR117599A1 (enExample)
AU (1) AU2019293727B2 (enExample)
BR (1) BR112020026405A2 (enExample)
CA (1) CA3104956C (enExample)
CL (1) CL2020003300A1 (enExample)
DK (1) DK3814331T3 (enExample)
EA (1) EA202092821A1 (enExample)
ES (1) ES2956045T3 (enExample)
FI (1) FI3814331T3 (enExample)
HU (1) HUE063538T2 (enExample)
IL (2) IL310623A (enExample)
LT (1) LT3814331T (enExample)
MX (1) MX2020014258A (enExample)
PH (1) PH12020552269A1 (enExample)
PL (1) PL3814331T3 (enExample)
PT (1) PT3814331T (enExample)
PY (1) PY1950412A (enExample)
SI (1) SI3814331T1 (enExample)
SM (1) SMT202300334T1 (enExample)
TW (1) TWI748194B (enExample)
UY (1) UY38283A (enExample)
WO (1) WO2020002611A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3796975T3 (da) 2018-05-22 2023-12-04 Orsobio Inc Sulfonylaminobenzamidderivater
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CA3177531A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
EP4188931A2 (en) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
JP2025540601A (ja) * 2022-11-03 2025-12-16 オルソバイオ， インコーポレイテッド 脂質異常症を治療するための二環式のコア部分を有するｌｘｒ調節因子

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508286A (ja) 2003-10-10 2007-04-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス薬としてのインドール及びアザインドール
JP2007523087A (ja) 2004-02-11 2007-08-16 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｌｘｒモジュレーターとしての化合物および組成物
JP2010506954A (ja) 2006-10-18 2010-03-04 ワイス エルエルシー キノリン化合物
JP2012515759A (ja) 2009-01-26 2012-07-12 ドマン・テラプーテイツク 新規なアデノシン受容体リガンドおよびその使用
US20150291563A1 (en) 2012-10-25 2015-10-15 Yuhan Corporation 4,5-dihydro-1h-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same
WO2016207217A1 (en) 2015-06-23 2016-12-29 Les Laboratoires Servier New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
JP2018501315A (ja) 2014-12-22 2018-01-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＴＧＦβ受容体アンタゴニスト

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308850A (en) 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
JPH06145150A (ja) 1992-11-09 1994-05-24 Kyowa Hakko Kogyo Co Ltd イミダゾール誘導体
AU4967797A (en) 1996-11-19 1998-06-10 Kyowa Hakko Kogyo Co. Ltd. Benzofuran derivatives
HUP9903330A2 (hu) 1996-11-19 2000-03-28 Amgen Inc. Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
AU757059B2 (en) 1997-06-19 2003-01-30 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
ATE499365T1 (de) 1997-10-24 2011-03-15 Nissan Chemical Ind Ltd Sulfamoyl-verbindungen und bakterizide für landwirtschaft oder gartenbau
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
WO2002018335A1 (en) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Cyclic amine derivatives
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
EP1343756A2 (en) 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6503907B2 (en) * 2000-11-28 2003-01-07 Hoffmann-La Roche Inc. Indole and dihydroindole derivatives
EA200300717A1 (ru) 2000-12-22 2003-12-25 Уайт Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
JP2005521721A (ja) 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
MY135686A (en) 2002-06-24 2008-06-30 Schering Corp Indole derivatives useful as histamine h3 antagonists
ES2228267B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
WO2005085188A2 (en) 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
MXPA06012683A (es) * 2004-05-03 2007-01-16 Hoffmann La Roche Derivados de indolilo como moduladores de receptor x del higado.
WO2005113499A1 (ja) * 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
GT200500208A (es) * 2004-08-03 2006-03-02 Indazoles ùtiles para tratar enfermedades cardiovasculares
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
WO2006109633A1 (ja) * 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
CA2634235A1 (en) 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
ES2374581T3 (es) 2006-07-06 2012-02-20 Abbott Healthcare Products B.V. Derivados de azaindol con una combinación de agonismo parcial del receptor nicotínico de la acetilcolina e inhibición de la reabsorción de dopamina.
AU2008231789A1 (en) 2007-03-23 2008-10-02 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
PT2142533E (pt) * 2007-03-30 2012-01-19 Hoffmann La Roche Derivados de imidazolidinona
GB0708141D0 (en) * 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
RU2010111550A (ru) 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) 2,3-замещенные индольные производные для лечения вирусных инфекций
EP2195317B1 (en) 2007-08-29 2012-01-18 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
US8765757B2 (en) 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
CN102317285A (zh) 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
EP2245936A1 (en) 2009-04-27 2010-11-03 Bayer CropScience AG Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
JP6055468B2 (ja) 2011-07-15 2016-12-27 ヴィーブ ヘルスケア ユーケー リミテッド アザインドール化合物及びｈｉｖを治療するための方法
US9988377B2 (en) 2011-08-24 2018-06-05 The Trustees Of Columbia University In The City Of New York Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders
MX358696B (es) 2011-12-22 2018-08-31 Connexios Life Sciences Pvt Ltd Derivados de aza adamantano y lo usos de los mismos.
KR20130142801A (ko) 2012-06-20 2013-12-30 안국약품 주식회사 １１β－ＨＳＤ１ 효소의 억제활성을 갖는 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
WO2014085453A2 (en) 2012-11-29 2014-06-05 The Scripps Research Institute Small molecule lxr inverse agonists
JP6442475B2 (ja) * 2013-03-15 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
EP2990403A1 (en) 2014-08-29 2016-03-02 Novartis Tiergesundheit AG Anthranilamides, sulfonamides and nitro analogues derived therefrom as anthelmintics
HK1243636A1 (zh) 2014-11-18 2018-07-20 Rutgers, The State University Of New Jersey 用於治疗代谢疾病和癌症的新的线粒体解偶联剂
EP3458454B1 (en) 2016-05-18 2021-11-24 Rutgers, The State University of New Jersey 2-hydroxy-n-(benzo[d]thiazol-2-yl)benzamide derivatives as mitochondrial uncouplers for the treatment of metabolic diseases and cancer
UY37659A (es) * 2017-04-10 2018-10-31 Phenex Fxr Gmbh Moduladores del receptor x del hígado (lxr)
TWI683808B (zh) * 2017-07-18 2020-02-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有胺或(硫)醯胺之lxr調節劑
DK3796975T3 (da) 2018-05-22 2023-12-04 Orsobio Inc Sulfonylaminobenzamidderivater
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
US20200397807A1 (en) 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
JP2025540601A (ja) 2022-11-03 2025-12-16 オルソバイオ， インコーポレイテッド 脂質異常症を治療するための二環式のコア部分を有するｌｘｒ調節因子

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508286A (ja) 2003-10-10 2007-04-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス薬としてのインドール及びアザインドール
JP2007523087A (ja) 2004-02-11 2007-08-16 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｌｘｒモジュレーターとしての化合物および組成物
JP2010506954A (ja) 2006-10-18 2010-03-04 ワイス エルエルシー キノリン化合物
JP2012515759A (ja) 2009-01-26 2012-07-12 ドマン・テラプーテイツク 新規なアデノシン受容体リガンドおよびその使用
US20150291563A1 (en) 2012-10-25 2015-10-15 Yuhan Corporation 4,5-dihydro-1h-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same
JP2018501315A (ja) 2014-12-22 2018-01-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＴＧＦβ受容体アンタゴニスト
WO2016207217A1 (en) 2015-06-23 2016-12-29 Les Laboratoires Servier New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2007年，Vol.17, No.12，pp.3473-3479
Journal of Organic Chemistry，2018年，Vol.83, No.1，pp.323-329

Also Published As

Publication number Publication date
PL3814331T3 (pl) 2023-11-13
LT3814331T (lt) 2023-08-10
US12291523B2 (en) 2025-05-06
AU2019293727B2 (en) 2022-06-30
US20210147398A1 (en) 2021-05-20
IL279722B1 (en) 2024-03-01
SI3814331T1 (sl) 2023-08-31
TWI748194B (zh) 2021-12-01
SMT202300334T1 (it) 2023-11-13
EP3814331B1 (en) 2023-06-14
IL279722A (en) 2021-03-01
DK3814331T3 (da) 2023-08-14
EP3814331B9 (en) 2023-08-09
WO2020002611A1 (en) 2020-01-02
TW202019907A (zh) 2020-06-01
PY1950412A (es) 2021-10-27
PT3814331T (pt) 2023-07-04
FI3814331T3 (fi) 2023-08-23
ES2956045T3 (es) 2023-12-12
UY38283A (es) 2020-01-31
US20230357214A1 (en) 2023-11-09
US11970484B2 (en) 2024-04-30
MX2020014258A (es) 2021-05-27
US20240317726A1 (en) 2024-09-26
KR102678581B1 (ko) 2024-06-25
EA202092821A1 (ru) 2021-05-21
IL310623A (en) 2024-04-01
EP3814331A1 (en) 2021-05-05
CN112689630A (zh) 2021-04-20
KR20210025636A (ko) 2021-03-09
JP2021528451A (ja) 2021-10-21
AR117599A1 (es) 2021-08-18
NZ772148A (en) 2024-05-31
CA3104956C (en) 2023-11-28
PH12020552269A1 (en) 2021-07-19
IL279722B2 (en) 2024-07-01
AU2019293727A1 (en) 2021-02-04
BR112020026405A2 (pt) 2021-04-06
HUE063538T2 (hu) 2024-01-28
CL2020003300A1 (es) 2021-07-02
US11618747B2 (en) 2023-04-04
CA3104956A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
KR102678581B1 (ko) 바이사이클릭 코어 모이어티를 갖는 신규한 lxr 조절제
ES2964964T3 (es) Compuestos bicíclicos puenteados como moduladores del receptor X farnesoide
KR20210102328A (ko) THRβ 수용체 효능제 화합물 및 그의 제조 방법 및 용도
AU2014234909B2 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
MX2015002807A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble.
JP2020516669A (ja) 肝臓ｘ受容体（ｌｘｒ）調節剤
TWI683808B (zh) 含有胺或(硫)醯胺之lxr調節劑
WO2023165334A1 (zh) 酮酰胺类衍生物及其制药用途
CN106414443B (zh) 吡啶并嘧啶二酮衍生物
WO2005118543A1 (ja) キナーゼ阻害薬およびその用途
HK40052052B (en) Novel lxr modulators with bicyclic core moiety
HK40052052A (en) Novel lxr modulators with bicyclic core moiety
WO2020148325A1 (en) Neutral lxr modulators
EA045482B1 (ru) Новые модуляторы lxr с бициклическим центральным фрагментом

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220607

TRDD Decision of grant or rejection written
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221007

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230106

R150 Certificate of patent or registration of utility model

Ref document number: 7214086

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250